Tender

Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen

NHS ARDEN AND GREATER EAST MIDLANDS COMMISSIONING SUPPORT UNIT

This public procurement record has 1 release in its history.

Tender

06 Sep 2019 at 19:33

Tender Notice
Summary of the contracting process

NHS Arden and Greater East Midlands Commissioning Support Unit is seeking experienced providers to deliver treatment for adult patients with 5Q Spinal Muscular Atrophy (SMA) using the drug Nusinersen. This procurement falls under the health services industry category, with the tender currently in the planning stage and set to close on 27 September 2019. The contract is expected to commence on 2 January 2020 and will last for three years, with potential extensions up until 24 July 2024, aiming to treat approximately 600 eligible patients across various regions in the United Kingdom.

This tender presents a significant opportunity for healthcare providers, particularly those with expertise in neuromuscular disorders and the administration of complex treatments such as intrathecal injections. Businesses that can demonstrate adequate infrastructure for both treatment delivery and patient monitoring will be well-positioned to compete. Given the specific requirements outlined by NHS England, this tender is particularly suited for organisations that cater to specialised medical services and are familiar with compliance processes in public health contracts.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Start Free Trial Book a Demo
All Features Pricing

Notice Information

Notice Title

Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen

Notice Description

NHS Arden and Greater East Midlands CSU (AGCSU) on behalf of NHS England Specialised Commissioning is inviting suitably qualified and experienced providers to deliver Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen under the Compliance Process specified in Document 1 - Process Overview of process documentation. On 24 July 2019, NICE published Technology appraisal guidance on the use of the drug Nusinersen to treat patients with 5q Spinal Muscular Atrophy (SMA). This is a rare, genetic, neuromuscular disease, characterised by spinal motor neuron loss, muscle atrophy and motor impairment. SMA is debilitating for all patients and fatal for the worst affected; patients and their families can experience extremely high levels of burden. NHS England has agreed a 'Managed Access Agreement (MAA)' for the drug nusinersen for the treatment of eligible patients with spinal muscular atrophy (SMA). The NICE guidance sets out that the drug should only be made available to people who meet the criteria for treatment under the associated MAA. The key objectives of the Compliance Process are: to commission the service(s) to serve adult patients eligible to receive the treatment nationally. It is estimated that 600 patients (adults and children) will be treated in England over the lifetime of the contract. Patients' eligibility and population covered are described in section 4 of the Managed Access Agreement. This may include treating patients from the devolved nations. The Commissioner is seeking to appoint providers who have expertise in the treatment of adults with SMA (from 16-18 years of age, depending on local agreements) and who have the infrastructure both to be able to treat patients with nusinersen (which is given by intrathecal injection) and to collect detailed monitoring information about eligible patients. Providers will need to demonstrate that they are suitably qualified and can meet the agreed service requirements. Further information about scope and qualification requirements can be found in the process documentation published on the EU Supply eTender/Procurement portal (Quote/tender 36955). All communications regarding this opportunity will be managed via the EU Supply messaging service. Additional information: An agreement will be established with the successful applicants for a period of 3 (three) years with the Commissioner having the option to extend the contract until the end of the Managed Access Agreement (24 July 2024). To apply please visit https://uk.eu-supply.com/login.asp?B=UK Quote/tender 36955 - NHS England Spec. Commissioning - Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-b5fd17-71f47de6-c77d-4b72-a709-718bc752e200
Publication Source
Contracts Finder
Latest Notice
https://www.contractsfinder.service.gov.uk/Notice/2f322f04-287d-4461-83ba-ed6957027a73
Current Stage
Tender
All Stages
Tender

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Not Specified
Procurement Method Details
Other -
Tender Suitability
Not specified
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services

CPV Codes

85100000 - Health services

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
6 Sep 20196 years ago
Submission Deadline
27 Sep 2019Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
2 Jan 2020 - 1 Jan 2023 3-4 years
Recurrence
Not specified

Notice Status

Tender Status
Active
Lots Status
Not Specified
Awards Status
Not Specified
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS ARDEN AND GREATER EAST MIDLANDS COMMISSIONING SUPPORT UNIT
Contact Name
Neli Garbuzanova
Contact Email
neli.garbuzanova@nhs.net
Contact Phone
Not specified

Buyer Location

Locality
LONDON
Postcode
SE1 6LH
Post Town
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI44 Lewisham and Southwark
Delivery Location
TLC North East (England), TLD North West (England), TLE Yorkshire and The Humber, TLF East Midlands (England), TLG West Midlands (England), TLI London, TLJ South East (England), TLK South West (England), TLL Wales, TLN Northern Ireland
Local Authority
Southwark
Electoral Ward
St George's
Westminster Constituency
Bermondsey and Old Southwark

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts. 

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-b5fd17-71f47de6-c77d-4b72-a709-718bc752e200-2019-09-06T20:33:25+01:00",
    "date": "2019-09-06T20:33:25+01:00",
    "ocid": "ocds-b5fd17-71f47de6-c77d-4b72-a709-718bc752e200",
    "language": "en",
    "initiationType": "tender",
    "tender": {
        "id": "20190906203322-68205",
        "title": "Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen",
        "description": "NHS Arden and Greater East Midlands CSU (AGCSU) on behalf of NHS England Specialised Commissioning is inviting suitably qualified and experienced providers to deliver Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen under the Compliance Process specified in Document 1 - Process Overview of process documentation. On 24 July 2019, NICE published Technology appraisal guidance on the use of the drug Nusinersen to treat patients with 5q Spinal Muscular Atrophy (SMA). This is a rare, genetic, neuromuscular disease, characterised by spinal motor neuron loss, muscle atrophy and motor impairment. SMA is debilitating for all patients and fatal for the worst affected; patients and their families can experience extremely high levels of burden. NHS England has agreed a 'Managed Access Agreement (MAA)' for the drug nusinersen for the treatment of eligible patients with spinal muscular atrophy (SMA). The NICE guidance sets out that the drug should only be made available to people who meet the criteria for treatment under the associated MAA. The key objectives of the Compliance Process are: to commission the service(s) to serve adult patients eligible to receive the treatment nationally. It is estimated that 600 patients (adults and children) will be treated in England over the lifetime of the contract. Patients' eligibility and population covered are described in section 4 of the Managed Access Agreement. This may include treating patients from the devolved nations. The Commissioner is seeking to appoint providers who have expertise in the treatment of adults with SMA (from 16-18 years of age, depending on local agreements) and who have the infrastructure both to be able to treat patients with nusinersen (which is given by intrathecal injection) and to collect detailed monitoring information about eligible patients. Providers will need to demonstrate that they are suitably qualified and can meet the agreed service requirements. Further information about scope and qualification requirements can be found in the process documentation published on the EU Supply eTender/Procurement portal (Quote/tender 36955). All communications regarding this opportunity will be managed via the EU Supply messaging service. Additional information: An agreement will be established with the successful applicants for a period of 3 (three) years with the Commissioner having the option to extend the contract until the end of the Managed Access Agreement (24 July 2024). To apply please visit https://uk.eu-supply.com/login.asp?B=UK Quote/tender 36955 - NHS England Spec. Commissioning - Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen.",
        "datePublished": "2019-09-06T20:33:25+01:00",
        "status": "active",
        "classification": {
            "scheme": "CPV",
            "id": "85100000",
            "description": "Health services"
        },
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "East Midlands",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "East of England",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "London",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "North East",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "North West",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "Northern Ireland",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "South East",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "South West",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "Wales",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "West Midlands",
                        "countryName": "United Kingdom"
                    },
                    {
                        "region": "Yorkshire and the Humber",
                        "countryName": "United Kingdom"
                    }
                ]
            }
        ],
        "procurementMethodDetails": "Other -",
        "tenderPeriod": {
            "endDate": "2019-09-27T23:59:59+01:00"
        },
        "contractPeriod": {
            "startDate": "2020-01-02T00:00:00Z",
            "endDate": "2023-01-01T23:59:59Z"
        },
        "suitability": {
            "sme": false,
            "vcse": false
        },
        "mainProcurementCategory": "services",
        "documents": [
            {
                "id": "1",
                "documentType": "tenderNotice",
                "description": "Opportunity notice on Contracts Finder",
                "url": "https://www.contractsfinder.service.gov.uk/Notice/2f322f04-287d-4461-83ba-ed6957027a73",
                "datePublished": "2019-09-06T20:33:25+01:00",
                "format": "text/html",
                "language": "en"
            }
        ]
    },
    "parties": [
        {
            "id": "GB-CFS-113121",
            "name": "NHS Arden and Greater East Midlands Commissioning Support Unit",
            "identifier": {
                "legalName": "NHS Arden and Greater East Midlands Commissioning Support Unit"
            },
            "address": {
                "streetAddress": "80 London Rd, Skipton House",
                "locality": "London",
                "postalCode": "SE1 6LH",
                "countryName": "ENG"
            },
            "contactPoint": {
                "name": "Neli Garbuzanova",
                "email": "neli.garbuzanova@nhs.net"
            },
            "details": {
                "url": "https://www.england.nhs.uk/commissioning/spec-services/"
            },
            "roles": [
                "buyer"
            ]
        }
    ],
    "buyer": {
        "id": "GB-CFS-113121",
        "name": "NHS Arden and Greater East Midlands Commissioning Support Unit"
    }
}